PHRM 845-FINAL EXAM Flashcards
Pharmacotherapy of depression
Should we wait to start pt on antidepressant med until the criteria are met?
No; not if someone can really benefit from them
Risk factors for depression
-Female
-White
-Physical disability
-Prior episode/suicide attempt
-Middle age
-Low socioeconomic status
-Lack of social support
-Co-morbid medical disorder
-Single marital status
-Unemployed
-Stressful life events/adverse childhood experiences
-Co-morbid SUD
Risk of recurrence for depression
1 episode: 50-60% chance of having another episode
2 episodes: 70%
3 episodes: 90%
We want to treat patient to remission. Many patients will respond better if dose is ___. Many patients ___ (do/do not) get the dose they need.
Increased
Do not
Disease course
-Occurs at any age, but commonly seen in early adulthood 20s and 30s
-Symptoms may develop over days to weeks
-Usually see a response to treatment, but not aggressive enough to achieve remission
What is remission?
A period of 2 or more months with no symptoms or only 1-2 symptoms. –Remember that as humans, we all have sad/down days at some point in our lives.
**For depression diagnosis, 5-6 symptoms are needed.
**Remission is possible and is the tx goal
Recurrence
-Risk becomes lower over time as duration of remission increases
-Persistent, mild symptoms during remission is a predictor of recurrence
-Function deteriorates during the episode and goes back to baseline upon remission–help a patient remember their baseline and try to get back there.
DSM-5 diagnosis criteria for depression
At least one of the symptoms must be depressed mood or loss of interest or pleasure in doing things.
**Must cause clinically significant impairment in functioning
**No hx of mania or hypomania (Bipolar disorder)
**Not attributed to physiological effects of a substance of another condition
DSM-5 Diagnostic criteria mnemonic: SIGE CAPS
S: Sleep (insomnia/hypersomnia)–difficulty sleeping even though they are in bed all the time
I: Interest decreased (anhedonia)
G: Guilt/worthlessness
E: Energy loss/fatigue
C: Concentration difficulties – if this is the biggest complaint, check for depression (if not the biggest complaint, remember this can be a sx of ADHD or other mental health disorders)
A: Appetite change (increase or decrease)
P: Psychomotor agitation (revved up/restless) or retardation (no energy to get up and get around)
S: Suicidal ideation (QPR)–Question, plan, resources
Self-administered rating skills for depression
-Patient Health Questionnaire (PHQ-9)
-Quick inventory of depressive symptomatology self-report (QIDS-SR-16)
-Mood disorder questionnaire (MDQ)–to determine depression and rule out bipolar disorder
Goals of depression tx
- Reduce or eliminate signs and symptoms of depression
- Restore occupational and psychological functioning to baseline
- Reduce the risk of relapse and recurrence
- Reduce the risk of harmful consequences (suicidal ideation)
Choosing pharmacotherapy
**Similar efficacy between and within antidepressant classes
-Pt preference
-Prior med response: how pt used it, SE experienced, concerns for trying again, etc.
-Safety, tolerability, SE
-Co-occurring psychiatric and medical conditions
-Pharmacological properties
-Cost
Phases of treatment
Acute:
-6-12 weeks
-Goal: induce remission
Continuation:
-4-9 additional months (recommended for all pts)
-Goal: prevent relapse
Maintenance:
-pt specific duration
-often indefinite tx if greater than or equal to 3 major depressive episodes
-Goal: prevent reoccurrence
Risk of suicidality
Boxed warning for suicidality in ALL antidepressant medications (for pts 24 y/o or younger)
**Closely monitor pt for increased suicidality and changes in behavior during first 1-2 months of therapy and after any dosage changes
Pharmacological classes of antidepressants
-SSRI (widely used)
-SNRI (widely used)
-TCA
-MAO-i
-Novel agents/others
-Augmentation agents
Citalopram
*Drug Class
*Important info
SSRI
-Dose-dependent QTc prolongation
-Substrate for 2C19 and 3A4
Fluoxetine
*Drug Class
*Important info
SSRI
-Long half-life (96-144 hours)
-Activating potential
-ONLY ONE THAT DOES NOT HAVE TO BE TAPERED
-2D6 and 3A4 inhibitor (norfluoxetine is the metabolite)
Fluvoxamine
*Drug class
*Important info
SSRI
-Only SSRI for OCD
-1A2 and 2C19 inhibitor
Paroxetine
*Drug class
*Important info
SSRI
-MUST taper dose due to anticholinergic effects *only 1 that is anticholinergic
-Weight gain, sedation
-Septal wall defect risk to fetus (NOT USED FOR PREGNANT PATIENTS OR PATIENTS <18 Y/O)
-2D6 and 2B6 inhibitor
Sertraline
*Drug class
*Important info
SSRI
-More GI upset than other antidepressants